Raily Aesthetic Medicine International Holdings Limited Provided consolidated unaudited earnings guidance for the year ended 31 December 2022. For the period, the Board expects the Group to record a revenue of approximately RMB 165 million (2021: revenue of approximately RMB 188 million) and expects to record a loss attributable to owners of the parent of approximately RMB 16 million (2021: loss of approximately RMB18 million).
Raily Aesthetic Medicine International Holdings Limited
Equities
2135
KYG7356A1215
Healthcare Facilities & Services
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.153 HKD | +5.52% | +16.79% | -68.12% |
Apr. 19 | Raily Aesthetic Medicine International Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Raily Aesthetic Medicine Forecasts Wider Loss in 2023 | MT |
1st Jan change | Capi. | |
---|---|---|
-68.12% | 10.34M | |
-18.90% | 16.51B | |
+4.50% | 12.53B | |
+4.81% | 11.74B | |
+2.43% | 10.06B | |
+29.69% | 8.71B | |
-3.88% | 7.57B | |
+19.68% | 7.22B | |
+5.46% | 6.68B | |
-2.79% | 4.32B |
- Stock Market
- Equities
- 2135 Stock
- News Raily Aesthetic Medicine International Holdings Limited
- Raily Aesthetic Medicine International Holdings Limited Provides Consolidated Unaudited Earnings Guidance for the Year Ended 31 December 2022